PMID: 18309947

Rudin CM, Liu W, Desai A, Karrison T, Jiang X, Janisch L, Das S, Ramirez J, Poonkuzhali B, Schuetz E, Fackenthal DL, Chen P, Armstrong DK, Brahmer JR, Fleming GF, Vokes EE, Carducci MA, Ratain MJ
Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity.
J Clin Oncol. 2008 Mar 1;26(7):1119-27., 2008-03-01 [PubMed]
Sentences
No. Mutations Sentence Comment
28 ABCG2 p.Gln141Lys
X
ABCG2 p.Gln141Lys 18309947:28:127
status: VERIFIED
view ABCG2 p.Gln141Lys details
ABCG2 p.Val12Met
X
ABCG2 p.Val12Met 18309947:28:162
status: VERIFIED
view ABCG2 p.Val12Met details
 Recent studies suggest that gefitinib and erlotinib are substrates of ABCG2.32-35 Two nonsynonymous ABCG2 SNPs, 421 CϾA (Q141K, rs2231142) and 34GϾA (V12M, rs2231137), are common.36-39 The 141K polymorphism has been associated with lower expression and activity of ABCG2 and with higher accumulation of both gefitinib and erlotinib.35,36,40 A recent clinical study showed an association between 141K and diarrhea in patients treated with gefitinib.41 We have recently identified four functional polymorphisms in the 5Ј-regulatory region of ABCG2 (Poonkuzhali et al, manuscript submitted for publication). Login to comment